Compare Amylx Pharmaceuticals Inc (AMLX) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Deutsche Bank AG — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Deutsche Bank AG trades at $35.72 (market cap $68.30B). The key difference: Deutsche Bank AG is far larger — about 34.5× Amylx Pharmaceuticals Inc's market cap, and Deutsche Bank AG pays a 3.25% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DB | |
|---|---|---|
Market Cap | $1.98B | $68.30B |
Sector | Health | Financials |
52-Week High | $18.70 | $40.33 |
52-Week Low | $7.64 | $28.37 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Deutsche Bank (DB) trades at $35.77, up 1.05% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum with Q1 2026 EPS beating expectations at $1.24 versus $1.15, and net income margin improving to 21.98% in 2025. Recent news includes expansion into Saudi Arabia and a dividend of $1.00 payable in June 2026, reflecting strategic growth initiatives.
Outlook is cautiously optimistic given low P/E of 9.94 and P/B of 0.77, suggesting undervaluation, but risks include volatile cash flows with a net outflow of $33.10B in 2024 and mixed analyst sentiment with only 21% buy ratings. Investors should weigh earnings consistency against macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
